IGF-1 LR3
$Potent growth-factor analog; High-risk gray-market use
IGF-1 LR3 is a modified insulin-like growth factor designed to last longer and bind IGF-binding proteins differently than native IGF-1. It is discussed for muscle growth and recovery, but the biology also overlaps with glucose lowering and cell-growth signaling.
This compound is not appropriate for casual or unsupervised use. Human therapeutic use of growth factors requires careful indication and monitoring. Community claims about hypertrophy are not the same as controlled safety data.
Focus on hypoglycemia risk, cancer-theory concerns, organ or tissue growth signaling, edema, neuropathic symptoms, and the fact that a longer half-life can mean more prolonged adverse effects.
Classification details
- IGF-1 LR3 is a modified IGF-1 analog with altered binding characteristics and prolonged activity relative to native IGF-1.
- IGF-1 LR3 is a modified long-acting IGF-1 analog used in research/bodybuilding contexts, not standard mecasermin therapy. LR3 modification changes binding-protein interaction and risk profile.
- It promotes anabolic and glucose-disposal signaling through IGF-related pathways.
- It activates IGF-1 receptor signaling involved in growth, glucose disposal, and anabolic pathways. That same biology creates hypoglycemia and growth-signaling concerns.